Delivra Topical Creatine for Improving Muscular Power

NCT ID: NCT02960425

Last Updated: 2018-06-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

123 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-10-31

Study Completion Date

2017-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Creatine is a nutritional supplement that is often ingested to improve exercise performance. The advent of a new product that is applied to the skin overlying muscle offers potential benefit, if the creatine can be targeted to specific muscles. The investigators are testing a novel creatine cream to determine the effects on human muscular performance. The investigators are assessing the acute application of two different doses of the creatine cream on muscular power (determined by knee extension).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Creatine monohydrate is a popular nutritional supplement with athletes involved in sports involving strength and power. When creatine is orally ingested it combines with inorganic phosphate to form phorylcreatine (PCr) in skeletal muscle . Adenosine Triphosphate (ATP) is the immediate source of energy in muscle - during exercise ATP is broken down to Adenosine Diphosphate (ADP) and inorganic phosphate. Duration of high-intensity exercise is limited to a few seconds based on limited ATP stores in muscle. PCr acts to re-phosphorylate ADP to form ATP so that muscle contraction can continue at high intensities. After creatine monohydrate is ingested, high-intensity exercise capacity is increased because of the increased PCr stores in muscle.

Delivra Inc. has developed a topical cream containing creatine that is designed to penetrate the skin. The study purpose is to determine whether the topical cream, at two different doses, is effective for improving muscular strength and power.

The hypotheses are that the experimental topical creatine cream will be more effective than a placebo cream for improving muscular performance and that two consecutive applications of creatine cream is more effective than a single application for improving muscular performance.

The study involves a involves a double-blind placebo-controlled parallel group design. Participants (n=132) will be randomized to receive either a low dose (3.5 mL) or high dose (7 mL) of topical creatine.

The baseline assessment involves measuring muscular power during 5 sets of 15 repetitions of knee extension on a dynamometer, with each set separated by 1 minute rest, with each leg tested separately. At least 72 hours after the baseline testing, participants will receive either a high or low dose of the topical creatine cream applied to the quadriceps of one leg. The high-dose group will receive 3.5 mL of creatine cream 30 minutes and 15 minutes to one leg (randomized) before exercise testing (i.e. the same testing as performed in visit 2). They will receive 3.5 mL of placebo cream 30 and 15 minutes to the opposite leg before testing. The low-dose group will receive placebo cream 30 minutes before testing and creatine cream 15 minutes before testing to one leg; they will receive placebo cream 30 and 15 minutes before testing on the opposite leg. Testing on each leg will involve measuring muscular power during 5 sets of 15 repetitions of knee extension on the dynamometer, with each set separated by 1 minute rest.

The primary outcomes are average and peak power output.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Muscle Weakness

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HI Delivra TM Livsport preworkout cream

7 mL topical creatine cream

Group Type EXPERIMENTAL

Delivra TM Livsport preworkout cream

Intervention Type DIETARY_SUPPLEMENT

High versus low dose topical creatine

Placebo

Intervention Type DIETARY_SUPPLEMENT

Topical placebo

LO Delivra TM Livsport preworkout cream

3.5 mL topical creatine + 3.5 mL placebo cream

Group Type EXPERIMENTAL

Delivra TM Livsport preworkout cream

Intervention Type DIETARY_SUPPLEMENT

High versus low dose topical creatine

Placebo

Intervention Type DIETARY_SUPPLEMENT

Topical placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Delivra TM Livsport preworkout cream

High versus low dose topical creatine

Intervention Type DIETARY_SUPPLEMENT

Placebo

Topical placebo

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Physically active and able to pass Physical Activity Readiness Questionnaire

Exclusion Criteria

* Allergies to any ingredients in the cream
* Answering "yes" to Physical Activity Readiness Questionnaire
* Currently pregnant or breastfeeding,
* Presence of significant medical disorder that would compromise the participant's safety to take part in the trial (eg: cancer, immunosuppressed)
* History of alcohol or drug abuse within the past year
* Anyone using recreational drugs
* Use of performance enhancing drugs or supplements within 2 months including caffeine and creatine in supplement form
* Currently using other topical agents for treatment of pain or inflammation
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Saskatchewan

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Phil Chilibeck

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David Baranowski, Ph.D.

Role: STUDY_DIRECTOR

Delivra, Inc.

Philip Chilibeck, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

University of Saskatchewan

Jamie Burr, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

University of Guelph

Travis Saunders, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

UPEI

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Guelph

Guelph, Ontario, Canada

Site Status

University of Prince Edward Island

Charlottetown, Prince Edward Island, Canada

Site Status

University of Saskatchewan

Saskatoon, Saskatchewan, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

16-145a

Identifier Type: -

Identifier Source: org_study_id